Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials

European Journal of Clinical Pharmacology

Volumn 73, Issue 3, 2017, Pages 267-278

  Pan, Yu ^a   Hu, Chun ^a   Chen, Pei Hua ^a   Gu, Yan Hong ^b   Qiao, Qing Yan ^b   Pan, Li Hua ^b   Zhou, Dong Chi ^b   Gu, Hui Fang ^b   Fu, Shun Kun ^b   Jin, Hui Min ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

All cause mortality; Cardiovascular events; Major adverse events; Oral endothelin receptor antagonist

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; ATRASENTAN; AVOSENTAN; BOSENTAN; DARUSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; PLACEBO; SITAXSENTAN; ZIBOTENTAN;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL (TOPIC); DATA BASE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EISENMENGER COMPLEX; EMBASE; HEADACHE; HUMAN; LIVER TOXICITY; MEDLINE; META ANALYSIS; METASTATIC MELANOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SIDE EFFECT; SYSTEMIC SCLEROSIS; CHEMICALLY INDUCED; MORTALITY; ORAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 85004064347     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-016-2171-5     Document Type: Article

References (55)

1. Kohan DE, Rossi NF, Inscho EW, Pollock DM (2011) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91(1):1–77
2. Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47:731–759
3. Barton M, Yanagisawa M (2008) Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86(8):485–498
4. Kohan DE, Pollock DM (2013) Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 76(4):573–579
5. Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110(9):1959–1966
6. Mann JF, Green D, Jamerson K et al (2010) Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21(3):527–535
7. Weber MA, Black H, Bakris G et al (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374(9699):1423–1431
8. Raichlin E, Prasad A, Mathew V et al (2008) Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 52(3):522–528
9. Galiè N, Beghetti M, Gatzoulis MA et al (2006) Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1):48–54
10. Anand I, McMurray J, Cohn JN et al (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431):347–354
11. Lüscher TF, Enseleit F, Pacher R et al (2002) Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106(21):2666–2672
12. Packer M, McMurray J, Massie BM et al (2005) Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11(1):12–20
13. King TE Jr, Brown KK, Raghu G et al (2011) BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(1):92–99
14. Raghu G, Behr J, Brown KK et al (2013) Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158(9):641–649
15. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J; MUSIC Study Group (2013) Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 42(6):1622–1632
16. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P (2010) A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer 9:69
17. Barst RJ, Langleben D, Badesch D et al (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47(10):2049–2056
18. Corte TJ, Keir GJ, Dimopoulos K et al (2014) Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 190(2):208–217
19. Galiè N, Olschewski H, Oudiz RJ et al (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23):3010–3019
20. Galiè N, Rubin LJ, Hoeper M et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100
21. Humbert M, Barst RJ, Robbins IM et al (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24(3):353–359
22. Jaïs X, D’Armini AM, Jansa P et al (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52(25):2127–2134
23. Pulido T, Adzerikho I, Channick RN et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369(9):809–818
24. Rubin LJ, Badesch DB, Barst RJ et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896–903
25. Sandoval J, Torbicki A, Souza R et al (2012) Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 25(1):33–39
26. Fizazi K, Higano CS, Nelson JB et al (2013) Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31(14):1740–1747
27. James ND, Caty A, Borre M et al (2009) Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55(5):1112–1123
28. James ND, Caty A, Payne H et al (2010) Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 106(7):966–973
29. Miller K, Moul JW, Gleave M et al (2013) Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 16(2):187–192
30. Nelson JB, Fizazi K, Miller K et al (2012) Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118(22):5709–5718
31. Quinn DI, Tangen CM, Hussain M et al (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14(9):893–900
32. Bakris GL, Lindholm LH, Black HR et al (2010) Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 56(5):824–830
33. Black HR, Bakris GL, Weber MA et al (2007) Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9(10):760–769
34. Matucci-Cerinic M, Denton CP, Furst DE et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70(1):32–38
35. Andress DL, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan DE (2012) Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 91(13–14):739–742
36. de Zeeuw D, Coll B, Andress D et al (2014) The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25(5):1083–1093
37. Kohan DE, Pritchett Y, Molitch M et al (2011) Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22(4):763–772
38. Wenzel RR, Littke T, Kuranoff S et al (2009) Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20(3):655–664
39. Miyagawa K, Emoto N (2014) Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis 8(5):202–216
40. Kalra PR, Moon JC, Coats AJ (2002) Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85(2–3):195–197
41. Cowburn PJ, Cleland JG (2001) Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J 22(19):1772–1784
42. van Veldhuisen DJ, Poole-Wilson PA (2001) The underreporting of results and possible mechanisms of ‘negative’ drug trials in patients with chronic heart failure. Int J Cardiol 80(1):19–27
43. Barton M, Kohan DE (2011) Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol 172:255–260
44. Stuart D, Chapman M, Rees S, Woodward S, Kohan DE (2013) Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J Pharmacol Exp Ther 346(2):182–189
45. Ge Y, Bagnall A, Stricklett PK et al (2006) Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291(6):F1274–F1280
46. Guo X, Yang T (2006) Endothelin B receptor antagonism in the rat renal medulla reduces urine flow rate and sodium excretion. Exp Biol Med (Maywood) 231(6):1001–1005
47. Ohkita M, Wang Y, Nguyen ND et al (2005) Extrarenal ETB plays a significant role in controlling cardiovascular responses to high dietary sodium in rats. Hypertension 45(5):940–946
48. Baltatu OC, Iliescu R, Zaugg CE et al (2012) Antidiuretic effects of the endothelin receptor antagonist avosentan. Front Physiol 3:103
49. Dhaun N, MacIntyre IM, Kerr D et al (2011) Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57(4):772–779
50. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M (2012) Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 91(13–14):528–539
51. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM (2007) Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30(2):338–344
52. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J (2002) Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 121(6):1860–1868
53. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ (2007) Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 26(1):63–69
54. Fattinger K, Funk C, Pantze M et al (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69(4):223–231
55. Eriksson C, Gustavsson A, Kronvall T, Tysk C (2011) Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis 20(1):77–80